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ABSTRACT  
Glutamate excitotoxicity is involved in the pathogenesis of a variety of neurodegenerative 
disorders, including Alzheimer’s disease (AD), Parkinson’s disease (PD), and multiple sclerosis 
(MS). Kainic acid (KA), an analogue of excitotoxic glutamate, can elicit selective neuronal 
death in the brain of rodents, of which the pathological changes partially mimic the 
neurodegenerative disorders in humans. Experimental autoimmune neuritis (EAN) is an 
immune-mediated acute inflammatory disease of peripheral nervous system (PNS) and shares 
many characteristics of human Guillain-Barré syndrome (GBS). Thus EAN is considered to 
represent as an animal model to study pathogenesis and therapy of human GBS.  
 
Cytokines play a key role in neuroinflammatory disorders. In our studies, we attempted to 
explore the possible roles of tumor necrosis factor (TNF)-α and interferon gamma (IFN-γ) in 
experimental neurodegenerative and neuroinflammatory disorders. 
 
In Paper I, the role of TNF-α in KA-induced hippocampal neurodegeneration was studied by 
comparing TNF-α knockout (KO) mice with C57BL/6 wild type (WT) mice. After KA 
treatment, TNF-α KO mice showed more sensitivity to KA-induced neurotoxicity than WT 
mice, as demonstrated by more severe seizures, measurable behavior changes, greater neuronal 
degeneration and enhanced glial cell activation, as well as nitric oxide (NO) production. 
Additionally, KA-treatment up-regulated the expression of nuclear factor kappa B (NFκB) in 
TNF-α KO mice to a greater degree as compared to that in KA-treated WT mice. In Paper II, 
we aimed to further clarify the protective role of TNF-α in KA-induced hippocampal neuronal 
death in vitro and elucidated the potential signaling pathways. After 24-hours treatment with 
KA, comparing with WT mice, TNF-α KO mice showed more susceptibility to KA-induced 
neurotoxicity, as demonstrated by higher expression of lactate dehydrogenase (LDH) and lower 
neuronal survival rates, as well as elevated NO production. It is also evidenced that pretreated 
with anti-TNF-α antibody increased the production of LDH and NO, and decreased the 
neuronal survival rate. In contrast, neurons from WT mice pretreated with recombinant TNF-α 
were more resistant to KA induced neurotoxicity. TNF-α deficiency induced down-regulation 
of phospho-IκBα, total AKT and phospho-AKT, as well as up-regulation of phospho-p38 
MAPK expressions after KA treatment. The reverse results can be achieved in WT 
hippocampal neurons with TNF-α treatment, i.e. up-regulation of phospho-IκBα and AKT. In 
Paper III, to further explore the role of TNF-α in the pathogenesis of neuroinflammation, the 
animal model-EAN was introduced. TNF-α deficiency significantly attenuated the clinical signs 
of EAN. Further, anti-TNF-α receptor 1 (TNFR1) antibodies markedly suppressed the clinical 
severity of EAN. TNF-α deficiency down-regulated the production of interleukin (IL)-12 and 
NO, as well as enhanced the production of IL-10 in macrophages. In Paper IV, the role of IFN-
γ in the pathogenesis of EAN was investigated. The clinical signs of IFN-γ KO EAN mice were 
aggravated when compared with WT EAN mice. At the peak of EAN course, the IL-17A 
expressing cells in cauda equine (CE) and the levels of IL-17A in sera were elevated in IFN-γ 
KO mice. The proportions of MHC II, macrosialin, and IL-12 expressing cells, relative to total 
CE infiltrating cells were correspondingly higher in IFN-γ KO than WT mice with EAN.  
 
In summary, TNF-α may play a protective role in KA-induced excitotoxic neurodegeneration, 
while TNF-α exacerbates EAN via TNFR1 by inducing the proinflammatory phenotype of 
macrophage. IFN-γ deficiency enhanced the clinical severity of EAN via upregulating of IL-
17A and Th2 cytokines production. These findings have relevance for future studies on 
pathogenesis and treatment of neurodegenerative and neuroinflammatory disorders in humans. 
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1 INTRODUCTION 
 
 1.1 KAINIC ACID INDUCED EXCITOTOXIC NEURODEGENERATIVE 
ANIMAL MODEL  
Excitotoxicity is involved in the pathogenesis of various neurodegenerative disorders in 
the humans’ central nervous system (CNS), including Alzheimer’s disease (AD), 
Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS) and multiple sclerosis 
(MS). Kainic acid (KA), an analog of excitotoxic glutamate, can elicit selective 
neuronal death in the brain of rodents, of which the pathological changes partially 
mimic the neurodegenerative disorders of humans in the CNS (Pollard et al. 1994). 
Systemic (intravenous or intraperitoneal), intranasal, or local administration of KA 
result in a series of clinical manifestations and pathological changes in rodents, such as 
recurrent seizures, behavioral changes, oxidative stress production including the 
generation of reactive oxygen species (ROS), reactive nitrogen species (RNS), 
hippocampal neuronal death and glial cells activation, etc (Wang et al. 2005b). Thus, 
KA-induced neurodegeneration in rodents has been used as a model for exploring the 
pathogenesis of excitotoxicity in neurodegenerative disorders in humans (Zheng 2011).  
1.1.1 Generic characteristics of KA and KA receptors 
KA (C10H15NO4) was originally isolated from the seaweed called “Kaininsou” or 
“Makuri”. KA has been used as an anthelminthic compound to remove worms from gut. 
Subsequent studies indicated that KA is a nondegradable analog of glutamate and 30-
fold more potency in neurotoxicity than glutamate (Vincent and Mulle 2009). This 
neuroexcitant can bind to the kainate receptors (KARs). With activation of KARs, KA 
induces a number of cellular events, including the increase of influx of cellular Ca2+, 
production of reactive oxygen species (ROS), and mitochondrial dysfunction leading to 
neuronal apoptosis and necrosis (Wang et al. 2005b). KA has been extensively used as 
a specific agonist to mimic the effect of glutamate on neurodegenerative models, and 
KARs mediate most of effects of kainate to induce seizures and cause excitotoxic 
neuronal death. The KARs family is divided into two subfamilies, including glutamate 
receptors (GluRs) 5-7 and KAR1-2.  
 2 
1.1.2 Features of KA-induced neurodegenerative animal model 
In rodents, systemic administration of KA leads to a well-characterized seizure 
syndrome (Ben-Ari 1985; Chen et al. 2002; Mulle et al. 1998). During the first 20-30 
minutes after KA administration, the rodents show “staring” spells, followed by head 
nodding. Then, they stand upright and fall down, with numerous wet-dog shakes for 
around 30 minutes. One hour after KA treatment, the animals start to present with 
recurrent limbic motor seizures. In the following 1-2 hours, the limbic seizures develop 
into status epilepticus (Chuang et al. 2004).  
KARs are most abundant in CA3 region of hippocampus and the activation of KARs 
can increases glutamate efflux (Rodriguez-Moreno and Sihra 2004; Sari E. Lauri 2001). 
Systemic injection of KA produced extensive neuronal death, primarily within the 
hippocampus hilus, CA3, and CA1 areas (Lee et al. 2010). However, high dose of KA 
can also induce neurotoxicity in the medial amygdaloid nuclei. After KA administration, 
selective damage in the brain of rodents shows behavioral changes in many behavioral 
tests, including the water maze, the object exploration tasks, Y-maze test, elevated plus 
maze and open-field test due to spatial learning deficits or depression changes (Gobbo 
and O'Mara 2005; Groticke et al. 2008; Ratte and Lacaille 2006).  
1.1.3 Neurodegenerative animal model induced by intranasal 
administration of KA: our experience 
In the past ten years, our lab developed a model of KA-induced neurodegeneration by 
intranasal administration of KA into C57BL/6 mice (Chen et al. 2005; Chen et al. 
2002). C57BL/6 mice are widely used strain for transgenic studies, while they are 
resistant to systemic administration of KA (intravenous or intraperitoneal). Our 
intranasal administration of KA present almost same seizure activity as systemic 
injection of KA, which provides a valuable tool to explore the role of excitotoxicity in 
neurodegeneration using transgenic mice with C57BL/6 background. As to behavioral 
changes, intranasal administration of KA induced elevated levels of spontaneous 
activity in the open-field test and Y-maze test (Chen et al. 2002; Zhang et al. 2007b). 
We also found that KA treatment changed the degree of anxiety in the elevated plus 
maze (Zhang et al. 2013b). We have several speculations to clarify the mechanism as 
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regards how KA induces excitotoxic neurodegeneration through intranasal 
administration. Firstly, KA may reach the hippocampus via passive diffusion (Illum 
2000). Secondly, protracted postsynaptic stimulation by activating KARs in the 
olfactory nerves and olfactory bulb can be relayed through projections to the 
hippocampus and thus result in neuronal damage (Montague and Greer 1999). Thirdly, 
since the cerebrospinal fluid (CSF) has direct connection with the olfactory bulb, KA 
may directly enter the CSF via the nasal cavity (Mathison et al. 1998). Additionally, 
small molecular weight of less than 20 kDa drugs can directly transported from the 
nasal cavity to the CSF (Sakane et al. 1995). Finally, KA may reach the hippocampus 
via the blood circulation (Genter et al. 2009). 
1.2  INFLAMMATION IN NEURODEGENERATIVE DISORDERS 
Neuroinflammatory process is a defense mechanism aimed at protecting the nervous 
system from infectious insults and injury. Inflammation typically occurs as an acute 
response to injury and might play a benefit role in tissue repairing during recovery 
phase, It has been evidenced that inflammation is strongly associated with glial 
(microglia and astrocyte) activation and expression of  proinflammatory mediators in 
the CNS (Streit 2010). Thus, whether inflammatory reaction is helpful or harmful, 
which remains largely unknown. Neuroinflammation is involved in a wide variety of 
neurological diseases, such as PD and AD, and may also associate with stroke (Hirsch 
et al. 2005; McGeer and McGeer 2003; Zheng et al. 2003). For example, 
neuroinflammation may accelerate amyloid deposition that can activate microglia, 
producing a deleterious positive feedback loop in AD patients (von Bernhardi 2007). 
Traditionally, CNS was regard as “immune privileged” area. A major reason for this 
view is due to exist of blood brain barrier (BBB). A decade ago, investigations have 
been revealed an active interaction of the CNS with the immune system through 
cytokines and other inflammatory molecular (McGeer and McGeer 2001). Among the 
resident brain cells, microglia and astrocytes, as well as neurons are able to secrete 
cytokines that modulate the neurons after activated by various stimuli and insult 
(Schinder et al. 1996) .  
 4 
1.2.1 Glial cell activation in inflammation 
Glial cells, particularly microglia and astrocytes, produce cytokines and chemokines, as 
well as express their receptors. The activation of glial cell is accompanied with 
neuronal death, characterized by clustering of activated microglia and astrocytes in the 
injured hippocampal lesions (Chen et al. 2005; Ravizza et al. 2005).  
1.2.1.1 Microglia 
Microglia is the primary immunocompetent cells and main effector cells of the 
inflammatory responses in the CNS after injury, and interacts with other gliocytes and 
neurons (Mack et al. 2003). Microglia exert their functions through interacting with 
extracellular matrix composition under physiological conditions, whereas microglia 
may become activated and secrete a great amount of proinflammatory cytokines, 
chemokines, complements, and so forth under pathophysiological conditions (Mack et 
al. 2003). Microglia acts as phagocyte in response to injury. Some studies suggested 
that activated microglia may play a neuroprotective role in MS and its animal model, 
experimental autoimmune encephalomyelitis (EAE) by facilitating reparatory and 
regenerative processes (Napoli and Neumann 2010). However, in several CNS 
neurodegenerative diseases, such as AD and PD, microglia may initiate and exacerbate 
neuropathological changes through secreting proinflammatory and cytotoxic molecules 
(Marinova-Mutafchieva et al. 2009; Venneti et al. 2009). Activated microglia express 
major histocompatibility complex (MHC) class I, MHC class II, and costimulatory 
molecules, produce complements, cytokines (IL-1, IL-6, IL-12, IL-18, TNF-α, etc.), 
chemokines, ROS, and RNS and secrete proteases and excitatory amino acids, which 
contribute to the neuronal death (Mack et al. 2003; Penkowa et al. 2001; Walz 2000). 
The activation of microglia may serve as an “accomplice” in KA-induced excitotoxicity 
(Giaume et al. 2007). 
1.2.1.2 Astrocytes 
Astrocytes are the largest glial cell population within the CNS, and were formerly 
regarded as passive supporters of neurons in the past years. Astrocytes have important 
physiological properties, maintaining the functional integrity of the synapse and BBB, 
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as well as contributing to the extracellular matrix proteins. However, recent studies 
raised a new concept of neuron-glial intercommunication that astrocytes play a 
dynamic role by integrating neuronal inputs and modulating synaptic activity, whereby 
contributing to neurodegenerative development (Gill et al. 2008; Vesce et al. 2007). 
Astrocytes can prevent neurons from death by producing growth factors (Braun et al. 
2009; Dakubo et al. 2008; Sandhu et al. 2009). Moreover, astrocytes express most 
neurotransmitter receptors such as ionotrophic glutamate receptors (iGluRs) (Brand-
Schieber and Werner 2003). In pathological conditions, astrocytes may secrete ROS 
and proinflammatory factors, which  contribute to brain damage (Heneka et al. 2010). 
The expression of glial fibrillary acidic protein (GFAP), a marker for astrogliosis, has 
been shown to steadily increase from one day up to one month after intra-hippocampal 
or intraperitoneal injection of KA (Bendotti et al. 2000; Ding et al. 2000). Up-regulated 
transcription factors in astrocytes, such as nuclear factor kappa B (NFκB) and nuclear 
factor erythroid-2-related factor 2 (Nrf2) induce the production of neuroprotective 
molecules and exert its neuroprotective actions on the neighboring neurons (Vargas et 
al. 2008; Vargas and Johnson 2009).  
1.3 INFLAMMATORY MEDIATORS PRODUCTION AFTER KA-INDUCED 
INJURY 
Neurodegenerative disorders are associated with increased expression of  inflammatory 
mediators in the CNS, such as in AD and MS (Rojo et al. 2008). A large number of 
inflammatory mediators including nitric oxide (NO), IL-6, IL-12 and TNF-α are 
released by activated microglia and astrocytes after KA treatment, which can 
exacerbate or reduce neuronal damage and influence the disease process (Figure 1) 
(Colton and Wilcock 2010; Kerschensteiner et al. 2009; Walz 2000). The inflammatory 
mediators may affect the pathological process with regard to seizure activity, 
behavioral changes, as well as the neuronal cell death in KA-induced excitotoxicity 
(Chen et al. 2004). The inflammatory cytokines can be divided into pro- and anti-
inflammatory cytokines, which play the contradictory biological roles in the 
pathological process.  
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Figure 1. KA-induced glial cell activation and inflammatory molecule production. 
After KA treatment, activated microglia and astrocytes can induce production of proinflammatory 
cytokines, such as IL-1, IL-6, IL-12, IL-18, TNF-α and anti-inflammatory cytoknes, such as TGF-
β and IL-10, as well as induce chmokines (IP-10, MIP-1α, MIP-1β, MCP-1, IL-8, RANTES), 
chemokine receptors (CCR2, 3, 5, etc.), and cytokine receptors (IL-10R, IL-12R, IL-18R, IFNgR, 
TNFR, TGFβR, etc.) expression, as well as express neutrophins (NGF, BDNF, etc.), MHC class I 
and II, costimulatory molecules (CD80 and CD86), etc., which may either contribute to excitotoxic 
damage or be protective from KA injury.  
IL: interleukin; CCR: C-C chemokine receptor; IFNgR: interferon gamma receptor; TNF: tumor 
necrosis factor; TGF: transforming growth factor; IP: Interferon gamma-inducible protein; MIP: 
macrophage inflammatory protein; MCP: monocyte chemotactic protein; RANTES: regulated upon 
activation, normal T-cell expressed and presumably secreted; NGF: nerve growth factor; BDNF: 
brain-derived neurotrophic factor. 
1.3.1 TNF-α  
The inflammatory cytokine, tumor necrosis factor-α (TNF-α) is a 17 kDa protein, 
mainly produced by activated macrophages and T cells in the immune system and by 
microglia and astrocytes in the CNS. Initially it was characterized as having anti-tumor 
activity, but it was later found to play pleiotropic roles, often contradictory biological 
effects (Yang et al. 2002; Yang et al. 2013). Its functions are mediated by binding with 
two receptors, TNF-α receptor (TNFR) 1 and TNFR2 (Ware et al. 1991). TNF-α 
binding to it’s two receptors can activate three major signaling pathways. First, TNF 
receptors associate with the TNF receptor-associated death domain (TRADD) .This 
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results in recruitment of factor associated suicide (Fas), and subsequent activation of 
caspase-8, which is an apoptotic signaling cascade (Schneider-Brachert et al. 2004). 
Secondly, NFκB signaling pathway is activated. The process is initiated when 
phosphorylation of inhibitor of NFκB (IκB) via NFκB essential modulator occurs, 
which leads to the degradation of IκB. NFκB acts as either a transcriptional activator or 
repressor by binding to specific DNA sequences (Bonizzi and Karin 2004). The third 
pathway is the c-Jun N-terminal kinase (JNK) pathway. The activity of transcription 
factors, such as protein-1 and specificity protein-1 is enhanced after the activation of 
cascade, via JNK-mediated phosphorylation (Benasciutti et al. 2004). These 
transcription factors involve in cell differentiation, proliferation, and pro-apoptotic 
(Park and Bowers 2010). 
TNF-α is a key mediator in both acute and chronic systematic inflammatory 
processes, since it can stimulate the production of several inflammatory cytokines and 
chemokines and their receptors expression. TNF-α plays a crucial role in the glial–
neuronal interactions that influences memory mechanisms and neuropathic pains. TNF-
α alters synaptic transmission in rat hippocampal slices and produces a rapid exocytosis 
of α-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA) receptors in 
hippocampal pyramidal cells (Stellwagen and Malenka 2006; Tancredi et al. 1992). 
Additionally,  TNF-α can regulate synaptic strength and synaptic scaling (Beattie et al. 
2002; Stellwagen and Malenka 2006). TNF-α may be the necessary factor to maintain 
neuronal function in physiologic conditions. The pro-inflammatory effects of TNF-α 
are widely recognized to contribute to the pathogenesis of a variety of neurological 
diseases in humans, especially bacterial meningitis (Grandgirard et al. 2013), MS 
(Rossi et al. 2013) and cerebral malaria (Zhu et al. 2012), where inflammatory cells 
contribute significantly to locally elevated TNF-α levels. TNF-α has been proved to 
mediate the disruption of longterm potentiation and related memory mechanisms 
produced by amyloid and amyloid oligomers in AD models (Tobinick 2009; Wang et al. 
2005a). TNF-α also bears neuroprotective properties in contrast to its well-known 
deleterious role as a proinflammatory cytokine, which implies an intricate biological 
effect in immune and inflammatory responses mediated by TNF-α (Lu et al. 2008; 
Zhang et al. 2013b). For example, TNF-α deficiency worsened Listeria infection (Rothe 
et al. 1993) and the neuronal damage was enhanced after excitotoxicity in mice lacking 
the TNF-α receptors (Lu et al. 2008). Inhibition of TNF-α has been proposed as a 
potential method of modulating glial activation in neuroinflammatory disorders 
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involving both the brain and the spinal cord (Griffin 2008). Recently, it has been 
demonstrated that increased brain levels of TNF-α result in significant inhibition of 
seizures in mice induced by intrahippocampal injection of KA (Balosso et al. 2005). 
Therefore, it is speculated that TNF-α could play double roles in the CNS, which may 
depend on different conditions: enhancing NFκB pathway processing or attenuating 
NFκB activity, while simultaneously promoting other pro-apoptotic TNF-α signals 
(Kaltschmidt et al. 1999).   
Since high dose of local TNF-α can enhance efficacy of chemotherapy, TNF-α has 
been used for regional treatment of metastatic melanoma (Chu 2013). TNF-α 
antagonists (Remicade/Infliximab, Adalimumab/Humira and Golimumab) are used as a 
therapy for inflammatory bowel disease, cancer-related cachexia, leukemia and ovarian 
cancer (Thalayasingam and Isaacs 2011). The drugs exert their effects by blocking 
TNF-α signaling either utilize anti-TNF antibodies  to neutralize soluble TNF-α or 
fusing with extracellular domains of TNFR1 or TNFR2  to block the interaction of 
TNF-α with TNF-α receptors. Overall, even anti-TNF-α therapy has been used in 
autoimmune disorders; however, some side effects have been reported. For example, 
anti-TNF-α therapy may increased the risk of developing cancer. Yet, the potential 
effect of anti-TNF therapy requires further investigations.  
1.3.2 NO 
NO is an important signaling molecule, and involved in many physiological and 
pathological processes. NO represents as one of the principle features of activated 
macrophage/microglia, and is a major effector in the innate immunity. One of the 
hallmarks of excitotoxic neurodegeneration is the production of NO (Lau and 
Tymianski 2010). It has been proved that nitric oxide synthase (NOS) inhibitors can 
prevent cell death in glutamate-mediated neurodegeneration  in vitro study  (Dawson et 
al. 1991). KA administration increases the generation of ROS and RNS by neuroglia, 
and NO can be formed enzymatically from L-arginine by inducible NOS (iNOS) in 
neuroglia (Wiesinger 2001). Elevated production of NO by increased activity of iNOS 
is thought to contribute to KA-induced neuronal damage (Amor et al. 2010). 
Pretreatment with iNOS inhibitor can significantly attenuate KA-induced neuronal 
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death in the hippocampal CA3 area with concomitant suppress microglial activation 
(Byun et al. 2009). 
1.3.3 Transcription factors production after KA injury 
NFκB is a heterodimeric transcription factor that regulates the cell differentiation, 
proliferation and survival (Yang et al. 2002). Many factors, including pro-inflammatory 
cytokines, TNF-α, interleukin (IL)-1 and foreign antigens can induce NFκB activation 
(Goldminz et al. 2013). NFκB signaling is hypothesized to promote pro-survival signal 
cascades, indicating again the dichotomistic ability of TNF-α to induce both pro-life 
and pro-death cellular outcomes (Park and Bowers 2010). Activated NFκB proteins 
have been detected in many chronic inflammatory conditions, including inflammatory 
bowel disease and rheumatoid arthritis (Kaser et al. 2010; Tak et al. 2001) Although 
originally NFκB was associated with immune and inflammatory cell function, the 
realization that such transcription factors also have essential roles in coordinating 
antimicrobial immunity and maintaining barrier function (Ben-Neriah and Karin 2011; 
Gewirtz et al. 2000). Inhibition of NFκB was found to increase or even cause 
inflammation in the mice devoid of NFκB activity (Pasparakis 2009). Further studies 
are still necessary to clarify the function of NFκB. 
The p38 mitogen-activated protein kinase (MAPK) has been considered as a stress-
activated protein kinase that responds to external signals, including osmotic shock, 
inflammatory cytokines, ultraviolet light, and growth factors (Oeztuerk-Winder and 
Ventura 2012). P38 MAPK signalling pathway is involved in several disease models, 
including rheumatoid arthritis, psoriasis and AD (Johnson and Bailey 2003). In vitro 
study, TNF-α enhances the tetrodotoxin-resistant (TTX-R) Na+ current from wild-type 
but not from TNFR1 knockout mice, and such current is abolished by a p38 MAPK 
inhibitor; implying that TNF-α acts via TNFR1 and activates TTX-R Na+ channels via 
the p38 MAPK system (Jin and Gereau 2006). Another study by using TNFR1/TNFR2 
knockout mice have suggested a neuroprotective role of TNFR2 through p38 MAPK 
signaling (Yang et al. 2002). In a rat model with spinal nerve ligation enhanced the 
production of TNF-α and phosphorylation-p38 MAPK, and the TNF-α blockade can in 
turn suppress p38 MAPK activation (Schafers et al. 2003). Further study by using nerve 
injury animal models showed induced expression of soluble TNFR2 in dorsal root 
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ganglia neurons, resulting in decreased phosphorylation of p38 MAPK (Leung and 
Cahill 2010). The above studies suggested that there is a causal link between TNF-α 
and the p38-MAPK system. 
Protein kinase B (PKB)/AKT pathway is an essential pathway for cell survival since 
AKT plays a key role in up-regulation of anti-apoptotic proteins. AKT is a serine-
threonine kinase that is regulated mainly following activation of the second messenger 
phospholipid kinase phosphatidylinositol 3-kinase (PI3K) (Zhang et al. 2011). During 
apoptotic process, the PI3K/AKT pathway can enhance glial cell survival, maintain the 
integrity of endothelial cells, prevent neurodegeneration and provide tolerance against 
oxidative stress (Maiese et al. 2012). Experimental model targeted to block the 
activation of PI3K/AKT pathway can suppress medulloblastoma growth, reduce cancer 
growth through induction of autophagy and increase radiosensitivity in tumors (Chung 
et al. 2012; Fokas et al. 2012). In vitro study, cortical neurons after pre-treated with 
TNF-α were exposured to glutamate, a PI3K-dependent PKB/AKT phosphorylation 
was ensued by NFκB activation (Marchetti et al. 2004). AMPA receptors stimulation 
by glutamate can activate AKT-dependent pathway, and this activation can regulate 
cell survival (Noch and Khalili 2009). 
1.4 GUILLAIN-BARRÉ SYNDROME AND ITS ANIMAL MODEL 
EXPERIMENTAL AUTOIMMUNE NEURITIS  
Guillain-Barré syndrome (GBS) is an acute inflammatory demyelination disease in 
peripheral nervous system (PNS). GBS is the most common cause of the acute flaccid 
paralysis in developing countries and is characterized by acute progressive and 
symmetrical motor weakens of the extremities as well as bulbar and facial musculature 
(Newswanger and Warren 2004; Olive et al. 1997). Georges Charles Guillain and Jean-
Alexandre Barré, two French neurologists, who together with the doctor André Strohl 
firstly described the syndrome in 1916 (Guillain et al. 1916). Experimental autoimmune 
neuritis (EAN) is a useful animal model for GBS, which is mediated by CD4+ T cell 
and mirrors many of the clinical, immunologic, electrophysiologic and morphologic 
aspects of GBS in the human (Rostami 1995; Zou et al. 2000). 
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1.4.1 Generic features of GBS and classification of GBS 
         GBS is considered as a clinical syndrome with combination of rapidly progressive 
symmetric weakness in the limbs, sensory disturbance, hyporeflexia or areflexia, and 
albuminocytologic dissociation. The progressive phase of GBS usually last from a few 
days to one month (Newswanger and Warren 2004). About 73% patients reach a nadir 
of clinical function at one week (Newswanger and Warren 2004). Additionally, around 
85% of GBS patients achieve a fully recovery in 6 or 12 months (Kuwabara 2004). 
According to the clinical, electrophysiological, and pathological features, GBS can 
be divided into seven subtypes of acute peripheral neuropathy (Kieseier et al. 2004; 
Newswanger and Warren 2004), including acute inflammatory demyelinating 
polyneuropathy (AIDP) (Hughes and Cornblath 2005), acute motor axonal neuropathy 
(AMAN) (McKhann et al. 1993), acute motor-sensory axonal neuropathy (AMSAN) 
(Feasby et al. 1993), acute sensory neuronopathy (Sterman et al. 1980), acute 
pandysautonomia, Miller-Fisher syndrome (MFS) (Fisher 1956) and MFS-GBS 
overlapping syndrome (Mori et al. 2001). The 90% of all GBS cases in Europe and 
North America is AIDP (Hughes and Cornblath 2005). However, AMAN and AMSAN 
are more prevalent in Asia, South and Central America (Drenthen et al. 2011). 
1.4.2 Experimental autoimmune neuritis (EAN) 
Experimental autoimmune neuritis (EAN) is a CD4+ T cell-mediated acute 
inflammatory demyelinating disorders of the PNS that can be induced in rats, mice, 
rabbits and monkeys, which serves as an animal model for AIDP (Lehrich and Arnason 
1971). EAN can be induced by active immunization with whole peripheral nerve 
homogenate, or myelin proteins P0 or P2 or their neuritogenic peptides plus Freund’s 
complete adjuvant (Rostami et al. 1990; Zou et al. 2000) or by passive transfer of P0, 
P2 as well as their peptide-specific CD4+ T cell lines (Maurer et al. 2002). 
The pathological hallmark of EAN is the breakdown of the blood nerve barrier 
(BNB), demyelination in the PNS and robust accumulation of autoreactive T cells and 
macrophages (Zhang et al. 2010; Zhang et al. 2013a). The early sign of EAN is the 
alteration in BNB permeability and the inflammatory cell infiltration in the PNS (Hahn 
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et al. 1985). A critical step in the immune response of EAN is the blood-derived 
inflammatory cells across the BNB (Zhang et al. 2013a). Macrophages act as the main 
antigen presenting cells (APCs) in the PNS by expressing MHC-I, MHC-II, and co-
stimulatory molecules (Schmidt et al. 1992; Vass and Lassmann 1990). Macrophages 
secrete pro-inflammatory cytokines, including IL-1, IL-6, IL-12 and TNF-which 
further promote the T helper (Th)1 prolarization (Kieseier et al. 1999). After that, 
polarized Th1 cells further stimulate macrophage to express a proinflammatory 
phenotype (M1) (Heusinkveld et al. 2011). In acute phase, macrophages can directly 
attack the myelin by releasing of proinflammatory and noxious molecules (Jung et al. 
1993; Kiefer et al. 2001; Zhang et al. 2010). During recovery stage, M1 can strip off 
myelin and phagocytose myelin debri by Fc/complement receptors (Kiefer et al. 2001; 
Wohlleben et al. 2000). Macrophage, cytokines, chemokines, NO, matrix 
metalloproteinases (MMPs) and adhesion molecules also contribute to the pathogenesis 
of EAN. 
1.4.3 Cytokines in GBS and EAN   
Cytokines are secreted by immune cells and other cells, and exert their functions 
through binding to specific receptors (Tsang and Valdivieso-Garcia 2003; Zhu et al. 
1998). Cytokines involved in the pathogenesis of EAN and GBS include TNF-α, IFN-γ, 
IL-12 and IL-17, etc. The balance of pro- and anti-inflammatory cytokines will shape 
the outcome of the response of GBS and EAN (Figure 2). 
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Figure 2. Role of cytokines in the pathogenesis of EAN.   
EAN is characterized by breakdown of BNB and accumulation of inflammatory cells in the PNS. 
Th0 cells can differentiate into Th1 or Th2 cells depending on their milieu. Th1 differentiation is 
regulated by IFN-γ and IL-12 produced by macrophages, NK cells, Th1 cells per se and DCs. 
During the acute phase, the production of Th1 cytokines, such as IFN-γ, TNF-α, IL-1β and IL-6 are 
increased. These cytokines can activate macrophages to produce ROI and NO, and enhance their 
antigen presenting capacity by upregulating the expression of MHC II. However, Th2 cytokines 
such as IL-4 and IL-10 suppress the disease by palying an antiinflammatory role during the recover 
phase. Th2 cytokines including IL-4, IL-5, IL-10 and IL-13, provide potent help for B cell activation, 
which can produce antibodies, and Th2 cytokines can promote Ig class switching to IgG1, and 
downregulate proinflammatory macrophage activation. RORα and RORγt are important 
transcription factors for stimulating the Th0 cells to Th17 cells. The cytokines of Th17 cells can 
induce local inflammation and autoimmune reaction in the target organ. 
BNB: brood-nerve barrier; DCs: dendritic cells; GM-CSF: granulocyte-macrophage colony-
stimulating factor; Ig: immunoglobulin; NK: natural killer; NO: nitric oxide; ROI: reactive oxygen 
intermediates; ROR: retinoic acid-related orphan receptor; TLR: Toll-like receptor. 
 1.4.3.1 TNF-α   
TNF-α is a prototypical inflammatory cytokine and a key regulator in the immune and 
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inflammatory responses (Radhakrishnan et al. 2004; Zhang et al. 2007a), which is 
mainly produced by activated macrophages and T cells after tissue injury (Chaparro et 
al. 2012). TNF-α exerts its functions through binding its two receptors, 1 (P55) and 2 
(P75) (Kassiotis and Kollias 2001). Both TNFRs express on various cell types, 
especially activated CD4+ and CD8+ T cells. TNF-α has direct toxic effects on the 
Schwann cells (SCs) of rodents, thereby contributes to EAN development (Argall et al. 
1992; Duan et al. 2007). Injection of TNF-α into rat sciatic nerve produces 
inflammatory demyelination (Redford et al. 1995); anti-TNF-α antibodies and 
inhibitors of TNF-α synthesis play a protective role in EAN (Korn et al. 2001). 
Increased serum levels of TNF-α correlated directly with disease severity of GBS and 
the concentrations returned to normal in parallel with clinical recovery (Sharief et al. 
1993). The anti-inflammatory compounds down-regulated the production of TNF-α can 
suppress the clinical signs of EAN (Korn et al. 2001; Zou et al. 2000). However, TNF-
α also has a protective role, since TNF-α antagonist exacerbate the symptoms of MS 
patients (Ghosh 2012).  
The protective or deleterious effects of TNF-α may depend on the levels of its two 
receptors (Smith et al. 1994). In EAN model, TNFR1 deficiency ameliorates clinical 
syndrome in mice (Mao et al. 2010b). However, in EAE model, TNFR2 knockout mice 
showed enhanced expression of Th1 cytokines and T cell infiltration (Suvannavejh et al. 
2000).  
Suppressing TNF-α is considered as a therapeutic target in EAN. In our previous 
study, treatment with soluble TNFR1 ameliorated EAN (Bao et al. 2003). Moreover, 
inhibition of TNF-α reduces T-cell apoptosis and prevents liver necrosis in EAN (Mao 
et al. 2010a). Nevertheless, further studies are still needed in clinical works.           
1.4.3.2 IFN-γ 
IFN-γ, acts as a typically cytokine for the Th1 response, is produced by T cells, natural 
killer (NK) cells and professional APC. IFN-γ was originally characterized as a 
molecule to mediate an immediate defensive response against viral infections (Pestka et 
al. 1987). IFN-γ exerts its function by activating IFN-γ receptors, 1 (IFNGR1) and 
IFNGR2 (Pestka et al. 1997). IFN-γ plays a crucial  role as a general proinflammatory 
molecule, including activation of macrophages, increasing the expression of MHC-I 
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and MHC-II on the APC, enhancing the differentiation of T cells to Th1 phenotype, 
while suppressing Th2 and Th17 responses, as well as modulating leukocyte trafficking 
(Lu and Zhu 2011). IFN-γ also can augment the production of other inflammatory 
cytokines, such as  TNF-α, IL-1β, IL-6, and receptor activator of NFкB (Schroder et al. 
2004). IFN-γ can induce the expression of cytokines and chemokines required for the 
recruitment of myeloid cells to the site of inflammation, and increase the expression of 
Toll like receptors (TLRs), and phagocyte oxidase by macrophages (Hu and Ivashkiv 
2009).  
The role of IFN-γ in GBS and EAN has been widely investigated. There was 
elevated IFN-γ expression in serum of GBS patients, however “paradoxical” findings 
have been indicated that IFN-γ plays the protective role in some models of autoimmune 
diseases, such as EAE and asthma (Flaishon et al. 2002; Willenborg et al. 1996). It’s 
also reported that the levels of IFN-γ-secreting cell were not increased in the whole 
course of GBS (Hohnoki et al. 1998; Press et al. 2001). IFN-γ KO mice showed 
ameliorated EAN severity, furthermore, anti-IFN-γ antibody treatment shortened the 
EAN course (Elkarim et al. 1998; Zhu et al. 2001). Several studies indicated that IFN-γ 
function changes may accord to the different stages of autoimmune 
diseases. Administration of IFN-γ in the early phase of EAE can attenuate disease 
severity, however, administration of IFN-γ at later stage of EAE can aggravate the 
clinical signs (Wildbaum et al. 2010). These findings suggest that IFN-γ might have 
dual roles in the pathogenesis of GBS and EAN. 
1.4.3.2 IL-12 
IL-12 , mainly produced by macrophages, neutrophils and dendritic cells (DCs), is  a 
heterodimeric cytokines composed of subunits p35 and p40 (Watford et al. 2003). IL-
12 mediates cellular immunity by inducing T cell and NK cells proliferation and 
promoting production of IFN-γ (Del Vecchio et al. 2007). IL-12 promotes the 
polarization of CD4+ T cell to the Th1 phenotype that plays the major role in the 
initiation, enhancement and perpetuation in the immune response to pathogens in EAN 
(Watford et al. 2003). Il-12 mRNA is expressed on the sciatic nerve sections over the 
course of EAN and was maximally up-modulated at height of clinical EAN (Zhu et al. 
1997). The administration of recombinant IL-12 prolonged the course of EAN and 
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exacerbated chronic EAN (Pelidou et al. 2000a). Moreover, IL-12 deficient mice 
exhibited attenuated clinical severity through decreasing production of TNF-α and IFN-
γ in inflamed nerves (Bao et al. 2002).  
1.4.3.2 IL-10 
IL-10 is an anti-inflammatory cytokine which primarily produced by monocytes, 
macrophage, and different T cell subsets (Sabat 2010). IL-10 suppressess 
proinflammatory cytokines production such as IL-1β and TNF-α and represses 
expression of MHC and co-stimulatory molecules, and inhibits their antigen presenting 
functions (Sabat 2010). IL-10 promotes the Th2 polarization through inhibiting IFN-γ, 
as well as enhances MHC II expression on B cells. The main function of IL-10 in 
inflammatory and autoimmune is the limitation and termination of inflammatory 
response and regulation of differentiation and proliferation of immune cells (Bashyam 
2007). Low dose of IL-10 administration promoted better regeneration of the damaged 
axons (Atkins et al. 2007). Maximal expression of IL-10 was observed after clinical 
recovery from EAN (Zhu et al. 1998). Furthermore, in the progressive phase of 
GBS, the expressions of IL-10 were significantly upregulated (Nyati et al. 2011).  
1.4.3.2 IL-17 
IL-17 family includes six members, namely IL-17A-F. IL-17A, the fundamental 
member of this family, is a signature cytokine which is released by Th17 cells and has 
been found to play important roles in autoimmune diseases, host defense, allergy, etc 
(Song and Qian 2013). IL-17A exhibits its inflammatory effects through upregulation 
of proinflammatory cytokines (IL-6, TNF-α and IL-1), chemokines, antimicrobial 
peptide and matrix metalloproteinases (MMPs) (Zhu and Qian 2012). IL-17 
administration enhanced the clinical signs during acute phase and suppressed the 
chronic phase of the EAN (Pelidou et al. 2000b). Furthermore, in IFN-γ deficiency 
EAN mice, significantly worse signs may related to higher percentages of IL-17A-
producing cells from cauda equina and the levels of serum IL-17A (Zhang et al. 2012a). 
Consistently with this, another study in our group found the level of IL-17A in cauda 
equina-infiltrating cells and spleen were correlated with the clinical severity of EAN, 
which might imply the underlying involvement of IL-17A in EAN (Zhang et al. 2012b). 
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The serum level of IL-17A was elevated in GBS patients (Liang et al. 2012). We also 
reported the same finding that the levels of IL-17A and IL-22 in CSF and plasma of 
GBS patients in the acute phase was increased (Li et al. 2012). These findings suggest 
that IL-17A may involve in the pathogenesis of GBS and EAN.  
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2 AIMS OF THE STUDIES 
To identify the roles of TNF-α and IFN-γ in the experimental neurodegenerative and 
neuroinflammatory disorders. 
Specific aims: 
Study I:      To study the role of TNF-α in KA-induced neurodegeneration in vivo. 
Study II:   To investigate the role of TNF-α in the excitotoxic neurodegeneration in 
vitro.  
Study III:   To explore the role of TNF-α in the pathogenesis of EAN. 
Study IV:   To clarify the role of IFN-γ in the pathogenesis of EAN. 
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3. MATERIALS AND METHODS 
3.1 ANIMALS (STUDIES I-IV) 
TNF-α knockout (KO) as well as C57BL/6 wild-type (WT) male mice were used in 
Studies I and III. Embryonic day 16 (E16) from TNF-α KO mice as well as C57BL/6 
WT mice were used in Study II. IFN-γ KO mice were used in Study IV. The TNF-α 
KO mice and the IFN-γ KO mice had been generated through targeted disruption of the 
TNF-α gene and the IFN-γ gene, respectively, and being backcrossed to the C57BL/6 
strain. All mice were housed on a 12/12 light-dark schedule with water and food 
available ad libitum. Detailed accommodation and care complied with local 
legislations.  
3.2 KA ADMINISTRATION AND ASSESSMENT OF CLINICAL SIGNS 
(STUDY I)  
Mice were partially anesthetized with Isofluen. KA was slowly and gently dropped by 
micropipette into the noses of the mice. Doses of KA used were 40 mg per kg body 
weight in both studies. Age-, sex- and body weight-matched TNF-α KO mice and WT 
mice, respectively, received the same amount of distilled water intranasally as controls. 
Mice were monitored continuously for 5 h to register the onset and extent of seizure 
activity. Seizures were rated as follows: 0, normal; 1, immobilization; 2, rearing and 
falling; 3, seizures for less than 1 h; 4, seizures for 1-3 h; 5, seizures for more than 3 h; 
and 6, death. 
3.3 BEHAVIORAL TESTS (STUDY I) 
3.3.1 Elevated Plus Maze ™  
The activities performed in the Elevated Plus Maze (EPM) tasks were measured before 
and after KA administration. The EPM consisted of two opposite open arms and two 
opposite closed arms surrounded by Plexiglas™ walls. The testing was carried out in a 
dimly lit room. The mouse was placed on the central area of the EPM facing an open 
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arm and tested for a 5 min period. An arm entry was defined as the entry of all four 
paws into the arm. The time spent, and the numbers of entries in the open and closed 
arms, respectively, were recorded.  
3.3.2 Y-maze  
The spontaneous alteration behavior in a Y-maze was performed two days before KA 
and five days after KA treatment. The Y-maze is used for identification of 
discrimination learning, spatial alteration tasks, and working memory of rodents. Test 
subjects were placed in a Y-shaped maze for 6 min. All arm entries were sequentially 
scored, so that the total number of arm entries and the sequence of entries were 
recorded. Data were analyzed to determine the number of arm entries without repetition. 
3.3.3 Open-field test  
Open-field (OF) activity was measured three days before and four days after KA 
administration. The OF test is used for measuring exploratory behavior and 
spontaneous motor activity of the animals. The apparatus consisted of a transparent 
acrylic plastic box in which the floor was subdivided into 64 equal squares. A mouse 
was gently placed in the center of the box. Locomotor activity and rearing were 
recorded every 3 min for a period of 9 min. Locomotor activity was evaluated by 
counting the number of times the mouse crossed the floor squares with both hind paws. 
Rearing was evaluated by counting the number of times the mouse showed vertical 
attitude with the forepaws raised or placed on the walls.  
3.4 HISTOPATHOLOGICAL ANALYSIS (STUDY I) 
All mice were anesthetized with sodium pentobarbital and transcardially perfused with 
phosphate-buffered saline (PBS) five days after the administration of KA. The left 
hemisphere of each brain was fixed in 4% paraformaldehyde and kept in 10% sucrose 
until being frozen. Coronal sections (12-m slices) from -1.15, -1.94 and -2.80 mm, 
respectively, relative to the bregma were prepared according to the information in 
Franklin’s brain atlas (Franklin 1997). Sections were stained by Fluoro-Jade B (FJB) to 
evaluate degenerating neurons. 
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3.5 IMMUNOHISTOCHEMISTRY OF BRAIN SECTIONS (STUDY I)  
Frozen hippocampal sections were prepared as described above for 
immunohistochemistry. After washes with Tris buffer, the sections were blocked by 
“protein block” at room temperature (RT) for 30 min. Subsequently, they were exposed 
to rat antibodies to CD11b and rabbit antibodies to glial fibrillary acidic protein 
(GFAP), respectively, followed by staining with the avidin-biotin technique. 
Peroxidase-substrate solution DAB was added until the desired intensity of brown color 
developed. Omission of primary antibodies served as negative control. 
3.6 PREPARATION AND CULTURE OF PRIMARY HIPPOCAMPAL 
NEURONS (STUDY II) 
Primary cultures of hippocampal neurons were isolated at E16 from mice according to 
the method by Fath et al (Fath et al. 2009). Briefly, the hippocampi were carefully 
dissected out. Then the hippocampus was moved to the tube with Neurobasal medium 
including 1% L-glutamine, 2% B27 supplement. Then dissociate tissue fragment 
mechanically with a Pasteur pipette until have the cell suspension. Count the 
hippocampal neuronal cells and seed in 6-wells plate coated with 50 ug/ml poly-D-
lysine at a density of 2 x 105 cells per well. The cells were cultured at 37°C and 5% 
CO2 /95% O2 incubator. On the seventh day, cultures were treated with KA dissolved 
in PBS. After co-culture with KA 24 h, ice-cold lysis buffer was used to harvest the 
hippocampal neurons for subsequent experiments.  
3.7 MEASUREMENT OF LEVEL OF LACTATE DEHYDROGENASE (LDH) 
AND NEUROTOXICITY (STUDY II) 
LDH production was detected in the culture supernatants 24 hour after KA treatment by 
using Cytotoxicity Detection Kit and the kit directions were followed. The results were 
presented as “relative value of LDH production versus total protein”. 
Twenty-four hours after KA treatment, neuronal viability was determined by the 
method utilizing metabolic dye 3-(4, 5-Dimethylthiazol-2-yl) - 2,5-diphenyltetrazolium 
bromide (MTT) as described previously (Mosmann 1983); 1.25 mg/mL MTT solution 
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was added to each well of a 96-well plate. After 3 h of incubation, cells were lysed by 
adding 120 μL of isopropyl-HCl solution (37% HCl/isopropyl alcohol: 1/166) for 15 
min. The absorbance of each well was recorded at 595 nm with an automated ELISA 
reader.  
3.8 WESTERN BLOTTING (STUDIES I AND II) 
The hippocampal supernatants were prepared as described above. 50 µg of each sample 
were electrophoresed on a 12% polyacrylamide gel and transferred to nitrocellulose 
membranes. The membranes were then blocked in 5% nonfat dry milk in PBS-Tween 
20 for 1 h at RT with gentle agitation. After blocking, the membranes were incubated 
with appropriate primary antibody rabbit anti-phospho-p38 mitogen-activated protein 
kinase, phospho- IκBα, rabbit anti-mouse NFκB, rabbit anti-mouse AKT, rabbit anti-
mouse phospho-AKT or rabbit anti-mouse β-actin, overnight at 4°C. After extensive 
washing in PBS-Tween 20, membranes were incubated with peroxidase-conjugated 
secondary antibodies for 1 h at RT. The membranes were rinsed again. Enhanced 
chemiluminescent Western blotting detection reagents were used for exposure 
according to the manufacturer’s instructions. Densitometric analysis was performed 
using the Image J program. Results were presented as “relative densities to β-actin”. 
3.9 ANTIGEN (SUTIES III AND IV) 
The neuritogenic peptide 180-199 of the murine PNS myelin P0 protein, was 
synthesized by the 9-fluorenylmethoxycarbonyl solid-phase synthesis, purified by high-
performance liquid chromatography (HPLC) using a Vydac reverse-phase column, and 
analyzed by matrix-assisted laser desorption/ionization time-of-flight mass 
spectrometry.  
3.10 INDUCTION OF EAN AND ASSESSMENT OF CLINICAL SIGNS 
(STUDIES III AND IV) 
Emulsion of P0 peptide and Freund’s complete adjuvant (FCA) was prepared by gently 
adding P0 peptide solution in 0.9% saline to FCA being vortexed. FCA refers to 
Mycobacterium tuberculosis plus Freund’s incomplete adjuvant (FIA). EAN was 
   23 
induced by immunizing mice twice (days 0 and 8) via subcutaneous injection of 150 
mg P0 peptide 180–199, 0.5 mg Mycobacterium tuberculosis in 25 ml saline, and 25 ml 
FIA to the back of mice. All mice received 400, 300, and 300 ng pertussis toxin (PTX) 
by intravenous injection (via tail veins) on days -1, +1 and +3 post immunization (p.i.), 
respectively. EAN was scored as follows: 0, normal; 1, less lively, reduced tone of the 
tail; 2, flaccid tail; 3, abnormal gait; 4, ataxia; 5, mild paraparesis; 6, moderate 
paraparesis; 7, severe paraparesis; 0.5, intermediate clinical signs. 
3.11 LYMPHOCYTE PROLIFERATION TEST (STUDIES III AND IV) 
Mice were sacrificed at the height of EAN (day 28 p.i.) after perfusion with PBS. 
Spleens were removed and single cell suspensions of mononuclear cells (MNCs) in 
RPMI-1640 were prepared and cultured. Concanavalin A (ConA), P0 peptide 180–199  
and IL-23 were used as stimuli. After 60 h of cultivation with respective stimulus, the 
proliferation was assessed using the CellTiter 96® AQueous One Solution Cell 
Proliferation Assay according to the manufacturer’s instructions. Briefly, assays were 
performed by adding a small amount of the reagent directly to culture wells. The 
CellTiter 96® AQueous One Solution Cell Proliferation Assay contains a novel 
tetrazolium compound [3-(4,5-dimethylthiazol-2- yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS(a)]. The MTS tetrazolium compound 
is bioreduced into a colored formazan product soluble in cell culture medium by 
NADPH or NADH produced by dehydrogenase in metabolically active cells. After 4 h 
incubation, the absorbance at 490 nm was recorded with an ELISA reader. 
3.12 MACROPHAGE CULTURES (STUDIES III AND IV) 
Mice were sacrificed and standard lavage of the peritoneal exudates with serum-free 
culture medium DMEM/F12 was performed. The lavage fluid contained peritoneal 
exudate mononuclear cells (PEMs), which represented mainly macrophages. The 
single cell suspension was centrifuged at 300 x g for 10 min. The pellets were 
resuspended with DMEM/F12 supplemented with 5% fetal bovine serum (FBS), 100 
U/ml penicillin and 100 μg/ml streptomycin, and the concentration was adjusted to 
2×106 /ml. Macrophages were seeded in 5.3 cm Petri-dishes. The cells were 
stimulated with Lipopolysaccharide (LPS), recombinant IFN-γ, TNF-α, poly I:C and 
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combinations thereof at 37 °C. After 24 and 48 hours of incubation, respectively, the 
supernatants were collected for detection of cytokine and NO. After removal of the 48 
hours supernatant, 5 ml culture media with Brefeldin A was added. Cells were 
harvested for subsequent flow cytometric analysis after 6 hours.  
3.13 ISOLATION OF INFLITRATING CELLS IN CAUDA EQUINA (CE) 
(STUDIES III AND IV) 
Briefly, cauda equina (CE) fragments of spinal cords were carefully removed from PBS 
perfused mice, transferred to RPMI-1640, ground and passed through a 70 m cell 
nylon mesh. The resultant cells were suspended in 27% percoll in PBS and centrifuged 
at 1000g for 30 min at 4°C. The pellet was kept for further analysis. . 
3.14 ELISA (STUDIES III AND IV) 
A standardized procedure for the sandwich ELISA was established after optimization 
of experimental parameters. Briefly, monoclonal antibodies were coated onto standard 
ELISA plates in a volume of 100 ml/well overnight at 4°C. After washing three times 
with PBS, uncoated sites were blocked with 100 ml 10% FBS in PBS for 1 h at RT. 
Duplicates of samples or of recombinant standards were added and the plates were 
incubated for 1 h at RT. After washing, the plates were incubated with biotinylated 
detecting antibody for 2 h at RT. Then avidin-conjugated horseradish peroxidase (HRP) 
was added for 30 min. Color reaction was performed with 100 ml of 
tetramethylbenzidine (TMB) for 30 min and the reaction was terminated by adding 2 M 
sulfuric acid. The plates were immediately read at 450 nm with an ELISA reader. The 
concentrations of proteins were quantified by extrapolation from the standard curve. 
3.15 FLOW CYTOMETRY (STUDIES III-IV) 
Cells were harvested and washed with 1% BSA in PBS. For staining of molecules with 
extracellular expression, cells were incubated with FITC-, PE- and/or APC-conjugated 
antibodies. For staining of molecules with intracellular expression, cells were fixed 
with 2% paraformaldehyde and permeabilized with 0.5% freshly prepared saponin in 
PBS containing 1% BSA. The permeabilized cells were incubated with FITC-, PE- 
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and/or APC-conjugated antibodies for 15 min at RT. FITC-, PE-, APC- and PerCP 
conjugated isotype antibodies were used as negative controls. After fixation and 
permeabilization, cells were washed twice, resuspended in 1% paraformaldehyde in 
PBS and stored at 4°C until flow cytometric analysis by a FACSCantoTM II cytometer 
using FlowJo or CellQuest software. Surface and intracellular molecule expression 
were assessed by determining the mean fluorescence intensities or positive cell 
percentages. Cells from all groups were collected and analyzed at each time point on 
the same day with the same cytometer settings. Values are presented for at least five 
mice per group. 
3.16 MEASUREMENT OF ANTI-P0 PEPTIDE ANTIBODIES IN SERA 
(STUDIES III AND IV) 
Serum samples were obtained from mice at the peak of EAN (day 28 p.i.). Purified P0 
peptide 180-199 was coated at 4 °C overnight by adding 10 μg/ml in 100 μl per well 
onto ELISA plates. After three washings with PBS, uncoated sites were blocked with 
100 μl 10% FBS in PBS for 2 hours at RT. After three washings with PBS, test serum 
samples were diluted to 1:100 with 1% BSA in PBS, applied to plate wells and 
incubated for 1.5 hours at RT. Then plates were incubated for 1hour with peroxidase-
conjugated affinipure rabbit anti-mouse IgM, IgG, IgG1, IgG2a, IgG2b after dilution 
to 1:5000 with 1% BSA in PBS (100 μl/well). After three washings, perioxidase 
substrate TMB was added and 15-30 minutes later the reaction was terminated by 
adding 1 M sulfuric acid. The plates were read at 450 nm using the ELISA reader. 
3.17 TNFR1 BLOCKING (STUDY III) 
Anti-TNFR1 monoclonal antibodies were administered intravenously to WT mice with 
EAN at a dose of 200 mg/(kg body weight) on days -1, +3 and +7 p.i., respectively. 
Another group of age- and sex-matched WT mice received 0.9% saline as controls. By 
using a blinded protocol, two examiners assessed clinical signs of EAN mice every two 
days. 
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3.18 DETECTION OF NITRIC OXIDE PRODUCTION (STUDIES I-IV)    
NO production was measured by the supernatant levels of nitrite, the stable biological 
oxidation product of NO, by using the modified Griess reagent. The detection 
procedure was performed according to the manufacturer's instructions. The 
concentrations of nitrite were quantified by extrapolation from the standard curve 
obtained by using sodium nitrite solutions at concentrations of 9, 3, 1, 0.33, 0.11, 0.033, 
and 0 μg/ml. 
3.19 STATISTICS (STUDIES I-IV) 
Each set of data was presented as mean value ± standard deviation (SD). One-way 
analysis of variance (ANOVA) and Kruskal Wallis test were used to compare values 
within groups followed by student’s t test and Mann-Whitney u-test to compare values 
between groups. All tests were two-tailed, and the level of significance was set to p 
<0.05. 
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4 RESULTS AND DISCUSSION 
4.1 STUDY I: TNF-α MAY PLAY A PROTECTIVE ROLE IN KA-INDUCED 
NEUROTOXICITY VIA THE DOWN-REGULATION OF NFκB 
SIGNALING PATHWAY 
After KA administration, TNF-α deficiency deteriorates KA-induced neurotoxicity, as 
demonstrated by more severe seizure activity and hippocampal neurodegeneration, 
changed behaviors, more activated microglia and astrogliosis, and increased NO 
production. Additionally, KA-treatment up-regulated the expression of NFкB to a 
greater degree in TNF-α KO mice when compared with KA-treated WT mice. 
TNF-α plays pleiotropic, often contradictory biological roles in neurodegenerative 
and neuroinflammatory diseases. TNF-α treatment in rats increased seizure 
susceptibility and enhanced level of TNF-α was found in an animal model of 
inflammatory bowel disease (Riazi et al. 2008). TNF-α derived from KA activated 
microglia aggravated excitotoxicity of hippocampal neurons, and might induce 
neuronal apoptosis in vitro and in vivo in rats (Zhu et al. 2010).  
KA-induced damage seriously impacted the hippocampus, which is particularly 
vulnerable to KA-induced neurotoxicity due to the high density of its kainate receptors 
(Darstein et al. 2003). CA3 region has the highest abundance of kainate receptors, the 
activation of which can elevate the concentration of reactive oxygen species (ROS) and 
impair the normal function of mitochondria (Carriedo et al. 2000; Lauri et al. 2001; 
Reynolds and Hastings 1995). CA3 neurons are directly excited by stimulation of their 
KA receptors, and indirectly by increased glutamate efflux secondary to KA 
stimulation of mossy fibers. CA3 synchronization produces spreading epileptiform 
activity that extends to CA1 and other limbic structures (Bausch and McNamara 2004; 
Ding et al. 1998). In this study, C57BL/6 WT mice displayed degenerating neurons in 
CA3 area, while TNF-α KO showed degenerating neurons in both CA3 and CA1 
regions.  
CA1 pyramidal neurons receive two distinct excitatory inputs that are capable of 
influencing hippocampal output, and thus involved in spatial memory and memory 
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consolidation (Iijima et al. 1996; Speed and Dobrunz 2009). Damage in CA1/CA3 
regions of hippocampus induced by KA mainly results in spatial learning deficits. We 
presented mice to a battery of behavioral tasks. Using the elevated plus-maze test, 
TNF-α KO mice showed fewer counts of head drops in open-arms compared with that 
of before KA treatment, indicating changed ability of risk assessment. However, we 
didn’t find any significant difference in the number of entries and time spent in each 
arm between TNF-α KO mice and WT mice before and after KA treatment, suggesting 
that KA may not influence the anxiety response in these mice ( ). Komada et al. 2008 In 
the open-field test, KA-treated TNF-α KO mice showed more locomotion activity in 
the first 6 minutes compared with KA-treated WT mice. And in 6-min Y-maze test, 
KA-treated TNF-α KO mice showed more total arm entries compared with KA-treated 
WT mice. However, no difference was obtained for the successful alteration between 
TNF-α KO and WT mice, either before or after KA treatment. It has been shown that 
KA-treated Wistar rats are impaired in the water maze and object exploration tasks, 
while hyperactive in the open field test (Gobbo and O'Mara 2004; Gobbo and O'Mara 
2005). Intraperitoneal injection of KA into the developing rat brain induces impaired 
short-term spatial memory in the radial-arm maze, deficient long-term spatial learning 
and retrieval in the water maze, and a greater degree of anxiety in the elevated plus 
maze(Sayin et al. 2004). 
KA-induced neuronal death is accompanied by increased activation of microglia and 
astrocytes. In the present study, TNF-α deficiency enhanced KA-induced microglia 
activation and astrogliosis in hippocampus. Microglia are the main effector cell type 
responsible for immune and inflammatory responses in the CNS. The normal role of 
microglia could be partly connected to neuroprotection, whereas in pathological 
conditions microglia may become disease-promoting cells. In KA-induced 
hippocampal injury, microglial activation is generally believed to contribute to 
neuroinflammation and neurodegeneration. Astrocytes have functional receptors for the 
excitatory neurotransmitter, glutamate, and respond to physiological concentrations of 
this substance with oscillations in intracellular Ca2+ concentrations and spatially 
propagating Ca2+ signals. Astrogliosis induced by excitotoxicity has been considered as 
a marker for neurotoxicity. Our results also showed that TNF-α deficiency increased 
KA-induced NO production in hippocampi. The activation of KA receptors produces 
membrane depolarization and results in alteration in intracellular calcium 
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concentrations, which is required to trigger the neuronal death cascade (Brorson et al. 
1994).  
TNF-α has a complex biological role in modulating immune and inflammatory 
responses, which functions are mediated through two receptors, TNFR1 and TNFR2. 
TNF binding with its receptors enables TNFR1-associated death domain protein 
(TRADD) to bind to the death domain. Following TRADD binding, NF-κB pathway 
can be activated. NF-κB is a heterodimeric transcription factor that translocates to the 
nucleus and mediates the transcription of a vast array of proteins involved in cell 
survival and proliferation, inflammatory response, and anti-apoptotic factors (Wajant et 
al. 2003). Additionally, the stimulatory effect of TNF-α can be mediated via the AKT 
signalling pathway. AKT is a serine/threonine protein kinase that plays a key role in 
multiple cellular processes such as glucose metabolism, cell proliferation, apoptosis, 
transcription and cell migration. We examined NFκB and AKT expression one and five 
days after KA treatment. Five days after KA treatment, TNF-α KO mice showed 
significantly higher NFκB expression than WT mice, and there was no difference for 
AKT expression among all groups of mice. We document that NFκB pathway, but not 
AKT, is important for KA-induced neurotoxicity, which agrees with a previous report 
(Marchetti et al. 2004).  
In summary, TNF-α deficiency deteriorates KA-induced neurotoxicity, as 
demonstrated by more severe seizure activity and hippocampal neurodegeneration, 
changed behaviors, more activated microglia and astrogliosis, and increased NO 
production. TNF-α may play a protecting role in KA-induced neurotoxicity via down-
regulation of NFκB signaling pathway. 
4.2 STUDY II: TNF-α PROTECTS HIPPOCAMPAL NEURONS FROM 
KAINIC ACID-INDUCED NEURODEGENERATION VIA UP-
REGULATION OF AKT AND DOWN-REGULATION OF P38 MAPK 
SIGNALING PATHWAYS 
In the present study, we found that hippocampal neurons from TNF-α deficient mice 
showed more susceptibility to KA-induced neurotoxicity, as demonstrated by 
obviously increased LDH and NO production, and decreased neuronal survival in the 
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primary cultures. Additionally, TNF-α deficiency clearly down-regulated the 
expression of phospho-IκBα and AKT, and up-regulated phospho-p38 MAPK 
expression in hippocampal neurons after KA insult. In WT mice, the pretreatment 
with anti-TNF-α increased LDH and NO expression, and aggravated KA-induced 
neurotoxicity in hippocampal neurons after KA insult. Furthermore, anti-TNF-α 
treatment distinctly down-regulated the production of phospho-IκBα,, AKT and 
phospho-AKT in hippocampcal cultures, as well as up-regulated the expression of 
phospho-p38 MAPK. However, the pretreatment with TNF-α in WT mice decreased 
LDH and NO expression, and attenuated KA-induced neurotoxicity in hippocampal 
neurons after KA insult. Furthermore, TNF-α treatment distinctly up-regulated the 
production of phospho-IκBα, AKT and phospho-AKT in hippocampcal cultures. 
The role of TNF-α in neurodegenerative disorders is diverse and complex. Over-
expression of TNF-α in transgenic mice is associated with the occurrence of age-
dependent neurodegenerative changes and sporadic spontaneous seizures. Antagonisms 
of TNF-α using a monoclonal antibody assist neuron survival. However, TNF-α deletion 
has also shown interesting effects on neuronal maturation and arborization. Golan et al. 
found that the dendritic arborization complexity of pyramidal neurons residing within 
the CA1 and CA3 regions of the hippocampus was reduced in the absence of TNF-α 
expression (Golan et al. 2004).  
The activation of KARs can induce the production of ROS and compromise the 
function of mitochondria in the region. KA stimulated the release of LDH, an indicator 
for loss of cell membrane integrity, suggesting KA induced damage to mitochondrial 
function. Hippocampal neurons from TNF-α KO mice displayed higher expression of 
LDH and lower cell survival than WT mice after 24 h KA treatment, which indicated 
that hippocampal neurons from TNF-α KO mice are more sensitive to KA induced 
neurotoxicity. Also after pretreated with anti-TNF-α, the expression of LDH was 
increased and the cell survival rate was lower compared with WT mice without anti-
TNF-α treatment. Pretreatment of TNF-α caused the lower expression of LDH and 
higher cell survival rate compared with WT mice without TNF-α treatment. 
NO is involved in many physiological and pathological processes within the CNS and 
can be formed enzymatically from L-arginine by inducible NO synthase (iNOS) in 
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neuroglia (Wiesinger 2001). Elevated production of NO by increased activity of iNOS is 
thought to participate in KA-induced neurotoxicity. In the present study, we observed 
that KA is capable of increasing the expression of NO in hippocampal neurons from KO 
mice or the WT mice pretreatment with anti-TNF-α. However, TNF-α treatment 
obviously reduced the expression of NO in WT mice after KA insult. 
The signaling pathway of p38 MAPK can regulate gene expression and lead to 
increased production of pro-inflammatory cytokines by a number of different 
mechanisms. P38 MAPK activity has also been associated with the induction of 
apoptosis in numerous cell types and in response to a multitude of stimuli,  such as 
osmotic shock, inflammatory cytokines, lipopolysaccharides (LPS). Our present results 
showed that TNF-α deficiency or pretreatment with anti-TNF-α enhanced the expression 
of p38 MAPK after KA insult. However, pretreatment with different dose of TNF-α 
didn’t influence the production of p38 MAPK after KA treated.  
IκBα is the prime target after AKT phosphorylation in the heterotrimeric IκB kinase 
complex, resulting in IκBβ activation and subsequent IκBα phosphorylation. AKT is 
necessary for neuronal survival since AKT plays a key role in up-regulation of anti-
apoptotic proteins. An established cell lines showed that PKB/AKT may serve as an 
IKK kinase in response to TNF-α treatment. In the study, after KA treatment, the 
hippocampal neurons from KO mice and WT mice with anti-TNF-α antibody treatment 
showed significantly lower expression of phospho-IκBα, AKT and phospho-AKT than 
WT mice without treatment, as well as TNF-α treatment in the hippocampal neurons of 
WT mice increased phospho-IκBα and phospho-AKT production compared with WT 
mice without TNF-α treatment.  
In conclusion, TNF-α may play a protective role in KA-induced neurotoxicity, which 
is via up-regulation of AKT and down-regulation of p38 MAPK signaling pathways. 
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4.3 STUDY III: ATTENUATED EAN IN TNF-α DEFICIENT MICE IS 
ASSOCIATED WITH AN ALTERED BALANCE OF M1/M2 
MACROPHAGES 
By inducing EAN in TNF-α KO mice, we found that TNF-α deficiency attenuated the 
clinical severity of EAN. The clinical signs of WT mice treated with TNFR1 antibodies 
were less severe than of the control WT mice receiving PBS. TNF-α deficiency induced 
an anti-inflammatory phenotype of macrophages (M2) characterized by reduced 
production of IL-12 and NO, and enhanced production of IL-10. Increased ratio of 
Tregs and reduced production of IFN-γ in infiltrating cells in CE were found in TNF-α 
KO mice with EAN.  
TNF-α signals through TNFR1 and TNFR2, mainly TNFR1, to elicit partly opposite 
reactions in multiple cell types. In the present study, TNF-α KO mice were not 
completely resistant to EAN induction. The reason could be that TNF-α is not a 
uniquely necessary inflammatory molecule for the induction of EAN. To further 
elucidate which receptor is responsible for the detrimental effect of TNF-α, we blocked 
the functions of TNFR1 in WT mice with EAN by using anti-TNFR1 monoclonal 
antibodies. The clinical severity of EAN was markedly mitigated after administration of 
the TNFR1 antagonist. However, this might also be due to the beneficial role of TNF-α 
acting via TNFR2. We then blocked the functions of TNFR1 in both TNF-α KO and 
WT mice with EAN and corroborated the detrimental role of TNFR1 in EAN. 
Activated macrophages can be divided into two distinct subsets: classically activated 
macrophages (M1) and alternatively activated macrophages (M2). Proinflammatory 
Th1 cytokines such as IFN-γ and IL-1β, and TLR agonist such as LPS and poly I:C 
induce the M1 phenotype, which is characterized by increased production of 
proinflammatory cytokines, e.g. IL-12, upregulated expression of MHC II, and 
enhanced generation of free radicals including NO (Gordon, 2003). We found a 
reduced ratio of IL-12/IL-10 in CE infiltrating cells and a lower level of IL-12 in 
unstimulated PEMs from TNF-α KO mice with EAN, indicating an antiinflammatory 
M2 phenotype of macrophages resulting from TNF-α deficiency.  
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We purified and cultivated macrophages in vitro and manipulated the culture milieu 
by adding various inflammatory stimuli. The proportion of more activated macrophages 
(higher levels of IL-6 and IL-12 expression) was lower in naïve than in EAN mice and 
lower in TNF-α KO than in WT mice with EAN. After cultured macrophages with 
proinflammatory stimulation, reduced levels of IL-12 and IL-6 and increased levels of 
IL-10 were produced from TNF-α KO mice compared with those from WT mice with 
EAN. Moreover, reduced production of NO was detected in culture supernatants of 
macrophages from TNF-α KO mice after proinflammatory challenge. The reduced 
production of NO in TNF-α KO mice may explain the attenuated clinical severity of 
EAN.  
In summary, TNF-α deficiency and TNFR1 blockade remarkably attenuated the 
clinical severity of EAN and TNF-α deficiency induced an anti-inflammatory 
phenotype of macrophages (M2).  
4.4 STUDY IV: IFN-γ DEFICIENCY EXACERBATES EAN IN MICE DESPITE 
MITIGATED SYSTEMIC TH1 IMMUNE RESPONSE 
IFN-γ deficiency exacerbates the clinical signs after the acute phase of EAN. The 
proliferation of splenic MNCs was significantly higher in IFN-γ KO than WT mice 
with EAN after antigenic stimulation. At the nadir of EAN, the proportion of IL-17A 
expressing cells in CE infiltrating cells, and the levels of IL-17A in sera were elevated 
in IFN-γ KO mice when compared with their WT counterparts. The proportions of 
MHC II, macrosialin, and IL-12/IL-23p40 expressing cells, relative to total CE 
infiltrating cells were correspondingly higher in IFN-γ KO than WT mice with EAN. 
However, IFN-γ deficiency reduced the production of NO by cultured macrophages in 
response to proinflammatory stimuli and induced a systemic Th2-oriented immune 
response. 
We initially hypothesized that IFN-γ deficiency might lead to an amelioration of the 
Th1 immune response, thereby attenuating the clinical severity of EAN. However, 
neither was the clinical course of EAN shortened, nor was the severity of EAN 
attenuated, although a mitigated Th1 immune response was remarkable in IFN-γ KO 
mice, evidenced by a reduced production of NO by cultured macrophages, and lower 
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production of Th1 cytokines including IL-6 and IL-12, as well as reduced levels of anti-
P0 peptide 180-199 IgG2a in sera. We thus postulated that the IL-17A and Th17 axis, in 
addition to IFN-γ may play a pathogenetic role in EAN.  
We then focused on the alteration of IL-17A production and found that IFN-γ 
deficiency induced increased infiltrating of Th17 cells in CE during EAN. In addition, 
IFN-γ deficiency enhanced the proportions of MHC II and macrosialin expressing cells 
in CE of mice with EAN. Functions of Th17 are inhibited by both Th1 and Th2 
cytokines (Harrington et al. 2005). Here, the protective role of IFN-γ in EAN might be 
due to its inhibition of Th17 development, since IFN-γ can prevent IL-23 triggered 
expansion of Th17 cells. Moreover, IFN-γ increases T-bet expression, the 
overexpression of which may in turn lead to a robust reduction of IL-17 generation. Of 
note is that in line with the traditional Th1/Th2 paradigm, IFN-γ deficiency induced a 
systemic Th2-oriented immune response, which may be beneficial to EAN. However, 
the pathophysiological effects resulting from the upregulated levels of IL-17A may 
outweigh the effects of the Th2-oriented immune response, and thus lead to the more 
severe clinical sysmptoms of EAN in IFN-γ deficient mice. An alternative explanation is 
that the exacerbated Th2 response may result in the generation of a pathogenic humoral 
response, as seen in many antibody-mediated autoimmune disorders (Sheikh et al. 2004). 
We excluded this possibility on the one hand because EAN is a well-accepted Th1-
mediated disease, and on the other hand because an aberrant level of Th2-associated 
IgG1 antibody was absent in IFN-γ deficient mice with EAN.  
More recently, we found a significantly increased proportion of Th17 cells in the 
peripheral blood and a higher level of IL-17 in the plasma of GBS in the acute phase (1-
14 days after the onset of disease); the level of IL-17 was correlated with the GBS 
disability scale score. By using a synthesized inorganic compound that specifically 
inhibits RORγt and Th17 cells, we found that EAN was significantly attenuated when 
the compound was administrated from the immunization day. These findings suggest 
that Th17 cells and their effector cytokines may be involved in the pathogenesis of GBS 
and EAN. Although the mechanism of action of IL-17A in EAN remains unclear, IL-
17A mainly acts as a proinflammatory cytokine that upregulates the expression of 
inflammatory genes including proinflammatory chemokines, hematopoietic cytokines, 
   35 
acute phase response genes and antimicrobial substances  in neutrophils, macrophages 
and endothelial cells (Zepp et al. 2011).  
In summary, IFN-γ deficiency exacerbated the clinical severity of EAN, concomitant 
with higher production of IL-17A and Th2 cytokines.  
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5 CONCLUSIONS 
1) TNF-α may play a protective role in KA-induced neurotoxicity via the down-
regulation of NFκB signaling pathway.  
2) TNF-α may play a protecting role in KA-induced neurotoxicity in vitro, which is 
via up-regulation of AKT and down-regulation of p38 MAPK signaling pathways 
3) Attenuated EAN in TNF-α deficient mice is associated with an altered balance of 
M1/M2 macrophages. 
4) IFN-γ deficiency exacerbates EAN via up-regulating Th17 cells despite a mitigated 
systemic Th1 immune response.  
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